Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 78.5%

Neg 0% Neu 0% Pos 78.5%

Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.